Page last updated: 2024-08-25

methotrexate and Myofibromatosis

methotrexate has been researched along with Myofibromatosis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's1 (12.50)24.3611
2020's4 (50.00)2.80

Authors

AuthorsStudies
Crazzolara, R; Entenmann, A; Kropshofer, G; Salvador, C1
Gehle, S; McShane, D; Quezada, G; Quinsey, C; Thompson, P1
Benchimol, G; Bodemer, C; Fraitag, S; Giacobbi, V; Orbach, D; Pierron, G; Proust, S; Starck, J1
Benish, M; Elhasid, R; Gortzak, Y; Levin, D; Manisterski, M; Sher, O; Shiran, SI1
Cederberg, K; Galindo, RL; Leavey, PJ; McCavit, TL; Wu, SY1
Abboud, M; Azzam, R; Khoury, N; Muwakkit, S; Saab, R1
Gandhi, MM; Levitt, GA; Nathan, PC; Weitzman, S1
Day, M; Edwards, AO; Leavey, PJ; Weinberg, A1

Reviews

1 review(s) available for methotrexate and Myofibromatosis

ArticleYear
Successful treatment of life-threatening generalized infantile myofibromatosis using low-dose chemotherapy.
    Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Critical Care; Dactinomycin; Female; Humans; Infant, Newborn; Male; Methotrexate; Muscle Neoplasms; Myofibromatosis; Osteolysis; Prednisolone; Remission Induction; Respiration, Artificial; Skin Neoplasms; Soft Tissue Neoplasms; Vinblastine; Vincristine

2003

Other Studies

7 other study(ies) available for methotrexate and Myofibromatosis

ArticleYear
New Therapeutic Approach in an Infant With Systemic Myofibromatosis and Intestinal Hemorrhage.
    Journal of pediatric hematology/oncology, 2022, Apr-01, Volume: 44, Issue:3

    Topics: Child; Dasatinib; Humans; Infant; Methotrexate; Myofibromatosis; Sirolimus; Vinblastine

2022
Infantile Myofibromatosis With Cutaneous, Visceral, and CNS Involvement: A Multimodal Approach to Therapy.
    Journal of pediatric hematology/oncology, 2023, 10-01, Volume: 45, Issue:7

    Topics: Female; Humans; Infant, Newborn; Methotrexate; Myofibromatosis; Vinblastine

2023
Major response to imatinib and chemotherapy in a newborn patient prenatally diagnosed with generalized infantile myofibromatosis.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Infant, Newborn; Male; Methotrexate; Myofibromatosis; Prognosis; Vinblastine

2021
Diverse presentation and tailored treatment of infantile myofibromatosis: A single-center experience.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:2

    Topics: Antineoplastic Agents; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Methotrexate; Myofibromatosis; Remission, Spontaneous; Retrospective Studies; Soft Tissue Neoplasms; Vinblastine

2021
Chemotherapy for Generalized Infantile Myofibromatosis With Visceral Involvement.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Female; Humans; Infant; Infant, Newborn; Male; Methotrexate; Myofibromatosis; Vincristine; Viscera

2015
First-line therapy of generalized infantile myofibromatosis with low-dose vinblastine and methotrexate.
    Pediatric blood & cancer, 2009, Volume: 52, Issue:2

    Topics: Disease-Free Survival; Humans; Infant; Male; Methotrexate; Myofibromatosis; Remission Induction; Vinblastine

2009
Brief report: successful therapy of a patient with infantile generalized myofibromatosis.
    Medical and pediatric oncology, 2002, Volume: 38, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Eye Neoplasms; Humans; Infant; Liver Neoplasms; Male; Methotrexate; Myofibromatosis; Treatment Outcome; Vinblastine

2002